期刊
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
卷 185, 期 -, 页码 664-678出版社
ELSEVIER
DOI: 10.1016/j.ijbiomac.2021.06.191
关键词
Antibody nanoconjugates; Molecular imaging; Cancer; Diagnosis; Therapy
资金
- Research Center for Pharmaceutical Nanotechnology (RCPN) , Tabriz University of Medical Sciences [67845]
Targeted imaging probes and drug delivery systems are major breakthroughs in nanomedicine for personalized medicine and cancer treatment. The conjugation of antibodies with nanoparticles allows for specific targeting of cancerous tissue, improving early detection and therapy outcomes.
Nowadays, the targeted imaging probe and drug delivery systems are the novel breakthrough area in the nanomedicine and treatment of various diseases. Conjugation of monoclonal antibodies and their fragments on nanoparticles (NPs) have a remarkable impact on personalized medicine, such that it provides specific internalization and accumulation in the tumor microenvironment. Targeted imaging and early detection of cancer is presumably the strong participant to a diminution in mortality and recurrence of cancer disease that will be the next generation of the imaging device in clinical application. These intelligent delivery systems can deliver therapeutic agents that target cancerous tissue with minimal side effects and a wide therapeutic window. Overall, the linkage between the antibody and NPs is a critical subject and requires precise design and development. The attachment of antibody nanoconjugates (Ab-NCs) on the antigen surface shouldn't affect the function of the antibody-antigen binding. Also, the stability of the antibody nanoconjugates in blood circulation is concerned to avoid the release of drug in non-targeted regions and the possible for specific toxicity while disposal to the desired site. Here, we update the recent progress of Ab-NCs to improve early detection and cancer therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据